Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353350 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
- 20
- Study locations
NCT03353350 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 406 participants, below the 2,745-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03353350, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight * To evaluate the safety of once-weekly injection of efpeglenatide
Conditions Studied
Interventions
- DRUG placebo
- DRUG efpeglenatide (SAR439977)
Study Locations (20)
California
- Investigational Site Number 8400003 - Canoga Park
- Investigational Site Number 8400007 - Chula Vista
- Investigational Site Number 8400011 - La Mesa
- Investigational Site Number 8400009 - Los Angeles
- Investigational Site Number 8400029 - Pomona
- Investigational Site Number 8400024 - Tarzana
- Investigational Site Number 8400026 - Van Nuys
Florida
- Investigational Site Number 8400010 - DeLand
- Investigational Site Number 8400006 - Hialeah
- Investigational Site Number 8400032 - West Palm Beach
Nevada
- Investigational Site Number 8400062 - Las Vegas
- Investigational Site Number 8400021 - Las Vegas
Alabama
- Investigational Site Number 8400004 - Birmingham
Arizona
- Investigational Site Number 8400005 - Glendale
Georgia
- Investigational Site Number 8400025 - Lawrenceville
Illinois
- Investigational Site Number 8400034 - Chicago
Missouri
- Investigational Site Number 8400033 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2020-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353350
The ClinicalTrials.gov registry entry for NCT03353350 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,745-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (85% lower). The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT03353350 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT03353350 about?
NCT03353350 is a clinical study titled "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise". Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: * To demonstrate th...
What is the current status of trial NCT03353350?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2017-12-05. Estimated completion is 2020-09-07.
What conditions does trial NCT03353350 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT03353350?
The interventions under investigation include: placebo (DRUG), efpeglenatide (SAR439977) (DRUG).
Who is sponsoring clinical trial NCT03353350?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03353350 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.